JPWO2020051356A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020051356A5 JPWO2020051356A5 JP2021512742A JP2021512742A JPWO2020051356A5 JP WO2020051356 A5 JPWO2020051356 A5 JP WO2020051356A5 JP 2021512742 A JP2021512742 A JP 2021512742A JP 2021512742 A JP2021512742 A JP 2021512742A JP WO2020051356 A5 JPWO2020051356 A5 JP WO2020051356A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- pharmaceutically acceptable
- acceptable salt
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 44
- 150000003839 salts Chemical class 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000036142 Viral infection Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 2
- 241000711549 Hepacivirus C Species 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 125000004982 dihaloalkyl group Chemical group 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000006682 monohaloalkyl group Chemical group 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 125000004385 trihaloalkyl group Chemical group 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862728556P | 2018-09-07 | 2018-09-07 | |
| US62/728,556 | 2018-09-07 | ||
| PCT/US2019/049784 WO2020051356A1 (en) | 2018-09-07 | 2019-09-05 | Imidazoquinoline compounds and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022501327A JP2022501327A (ja) | 2022-01-06 |
| JPWO2020051356A5 true JPWO2020051356A5 (https=) | 2022-07-04 |
| JP2022501327A5 JP2022501327A5 (https=) | 2022-07-04 |
Family
ID=69722888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021512742A Pending JP2022501327A (ja) | 2018-09-07 | 2019-09-05 | イミダゾキノリン化合物およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210214354A1 (https=) |
| EP (2) | EP4306523A3 (https=) |
| JP (1) | JP2022501327A (https=) |
| KR (1) | KR20210074290A (https=) |
| CN (1) | CN113164460A (https=) |
| AU (1) | AU2019335366A1 (https=) |
| CA (1) | CA3111786A1 (https=) |
| ES (1) | ES2963112T3 (https=) |
| WO (1) | WO2020051356A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105899539B (zh) | 2014-01-10 | 2021-11-09 | 博笛生物科技有限公司 | 用于免疫疗法的化合物和组合物 |
| EP3166976B2 (en) | 2014-07-09 | 2026-04-08 | Birdie Biopharmaceuticals Inc. | Anti-pd-l1 combinations for treating tumors |
| CN112587672A (zh) | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| CN115252792A (zh) | 2016-01-07 | 2022-11-01 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| CN115350279A (zh) | 2016-01-07 | 2022-11-18 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-her2组合 |
| CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| KR102726248B1 (ko) | 2016-07-07 | 2024-11-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| CN118515666A (zh) | 2017-04-27 | 2024-08-20 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| IL312120B2 (en) | 2017-06-23 | 2025-06-01 | Birdie Biopharmaceuticals Inc | Pharmaceutical compositions |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| CN115916342A (zh) * | 2020-07-08 | 2023-04-04 | 普渡研究基金会 | 用于治疗纤维化疾病和癌症的化合物、组合物和方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US689338A (en) * | 1901-03-29 | 1901-12-17 | Nat Faucet Company | Tapping-bung. |
| US5389640A (en) * | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| EP1667694B1 (en) * | 2003-09-05 | 2010-04-28 | Anadys Pharmaceuticals, Inc. | Tlr7 ligands for the treatment of hepatitis c |
| US20080213308A1 (en) * | 2004-09-14 | 2008-09-04 | Nicholas Valiante | Imidazoquinoline Compounds |
| US8728486B2 (en) * | 2011-05-18 | 2014-05-20 | University Of Kansas | Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds |
| WO2013033345A1 (en) * | 2011-08-30 | 2013-03-07 | Regents Of The University Of Minnesota | Immunomodulators and immunomodulator conjugates |
| MX377916B (es) * | 2014-04-22 | 2025-03-10 | Hoffmann La Roche | Compuestos 4-amino-imidazoquinolina. |
| CN105233291A (zh) * | 2014-07-09 | 2016-01-13 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| EP3166976B2 (en) * | 2014-07-09 | 2026-04-08 | Birdie Biopharmaceuticals Inc. | Anti-pd-l1 combinations for treating tumors |
| CN105732635A (zh) * | 2014-12-29 | 2016-07-06 | 南京明德新药研发股份有限公司 | 一类Toll样受体7激动剂 |
| CN115350279A (zh) * | 2016-01-07 | 2022-11-18 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-her2组合 |
-
2019
- 2019-09-05 US US17/274,136 patent/US20210214354A1/en not_active Abandoned
- 2019-09-05 ES ES19858183T patent/ES2963112T3/es active Active
- 2019-09-05 WO PCT/US2019/049784 patent/WO2020051356A1/en not_active Ceased
- 2019-09-05 KR KR1020217010120A patent/KR20210074290A/ko not_active Ceased
- 2019-09-05 EP EP23188546.8A patent/EP4306523A3/en not_active Withdrawn
- 2019-09-05 JP JP2021512742A patent/JP2022501327A/ja active Pending
- 2019-09-05 AU AU2019335366A patent/AU2019335366A1/en not_active Abandoned
- 2019-09-05 CA CA3111786A patent/CA3111786A1/en active Pending
- 2019-09-05 EP EP19858183.7A patent/EP3846807B1/en active Active
- 2019-09-05 CN CN201980068724.0A patent/CN113164460A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022501327A5 (https=) | ||
| JP2020507589A5 (https=) | ||
| JP2021522249A5 (https=) | ||
| JP2022031403A5 (https=) | ||
| JP2021063088A5 (https=) | ||
| JP2020125349A5 (https=) | ||
| JPWO2020051356A5 (https=) | ||
| JP3479068B2 (ja) | ５−フルオロ−２’−デオキシ−３’−チアシチジンのｂ型肝炎治療への使用 | |
| JP2024156774A5 (https=) | ||
| JP2009507909A5 (https=) | ||
| JP2021527638A5 (https=) | ||
| JP2019511483A5 (https=) | ||
| JP2012529486A5 (https=) | ||
| JP2006523216A5 (https=) | ||
| JP2021152063A5 (https=) | ||
| JPWO2021156180A5 (https=) | ||
| JP2005508337A5 (https=) | ||
| JP2021534160A5 (https=) | ||
| CN116113416A (zh) | 四环类衍生物、其制备方法和其医药上的用途 | |
| JPWO2020037091A5 (https=) | ||
| JPWO2020037092A5 (https=) | ||
| JP2022169780A5 (https=) | ||
| JPWO2021041237A5 (https=) | ||
| JPWO2020206289A5 (https=) | ||
| RU2008112181A (ru) | Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3 |